RESUMO
Presumptive antirelapse therapy (PART) with primaquine for Plasmodium vivax malaria postdeployment is an important component of the US military Force Health Protection plan. While primaquine is well tolerated in the majority of cases, we present a unique case of an active duty Army Ranger without glucose-6-phosphatase dehydrogenase or cytochrome b5 reductase (b5R) deficiencies who developed symptomatic methemoglobinemia while taking PART following a deployment to Afghanistan.
Assuntos
Metemoglobinemia/induzido quimicamente , Metemoglobinemia/diagnóstico , Militares , Primaquina/toxicidade , Campanha Afegã de 2001- , Diagnóstico Tardio , HumanosAssuntos
Lesões Encefálicas Traumáticas/diagnóstico , Lesões Encefálicas Traumáticas/terapia , Lesões Relacionadas à Guerra/diagnóstico , Lesões Relacionadas à Guerra/terapia , Lesões Encefálicas Traumáticas/complicações , Humanos , Exame Neurológico , Monitorização Neurofisiológica , Consulta Remota , Transporte de Pacientes , Lesões Relacionadas à Guerra/complicaçõesRESUMO
The authors describe the off-label use of Onyx for embolization of fusiform mycotic and dissecting intracranial aneurysms based on their experience with 3 patients treated at the University of Utah Hospital from 2006 through 2007. Technical success in occluding the parent artery/aneurysm was achieved in all patients. There were no complications. The authors conclude that Onyx can be used to achieve occlusion of fusiform mycotic and dissecting intracranial aneurysms in conjunction with parent artery occlusion.
